<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02739867</url>
  </required_header>
  <id_info>
    <org_study_id>PLATO-VTE</org_study_id>
    <nct_id>NCT02739867</nct_id>
  </id_info>
  <brief_title>Tumor-educated Platelets in Venous Thromboembolism</brief_title>
  <official_title>Platelet RNA Profiling to Detect Occult Cancer in Patients With Unprovoked Venous Thromboembolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Among patients with a first episode of unprovoked venous thromboembolism (VTE), the
      contemporary one-year risk of detecting occult cancer is approximately 4% to 7%. Of these
      cases, 30% to 60% are missed by routine limited screening for cancer. RNA profiling of
      platelets is a promising, highly accurate biomarker for cancer detection, but its clinical
      utility in patients with unprovoked VTE is unknown. The objective of the present study is to
      evaluate the diagnostic accuracy of platelet RNA profiling in detecting occult cancer in
      patients with unprovoked venous thromboembolism. Secondary objectives include evaluation of
      other biomarkers for cancer, prediction of bleeding, and prediction of recurrent VTE.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Any solid or hematological cancer</measure>
    <time_frame>Up to one year following venous thromboembolism</time_frame>
    <description>Adjudicated diagnosis of solid or haematological cancer which is confirmed by histology or cytology, or is unequivocally diagnosed by either imaging or tumour markers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early-stage solid cancer</measure>
    <time_frame>Up to one year following venous thromboembolism</time_frame>
    <description>Early-stage solid cancer, defined as stage I or II solid cancer according to the American Joint Commissee on Cancer criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent venous thromboembolism</measure>
    <time_frame>Up to one year following venous thromboembolism</time_frame>
    <description>Adjudicated recurrent VTE (see full definition in protocol)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>Up to one year following venous thromboembolism</time_frame>
    <description>Adjudicated major bleeding according to the International Society on Thrombosis and Haemostasis criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically relevant non-major bleeding</measure>
    <time_frame>Up to one year following venous thromboembolism</time_frame>
    <description>Adjudicated clinically relevant non-major bleeding according to the International Society on Thrombosis and Haemostasis criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of major bleeding and clinically relevant non-major bleeding</measure>
    <time_frame>Up to one year following venous thromboembolism</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Up to one year following venous thromboembolism</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer-related mortality</measure>
    <time_frame>Up to one year following venous thromboembolism</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solid cancer</measure>
    <time_frame>Up to one year following venous thromboembolism</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematological cancer</measure>
    <time_frame>Up to one year following venous thromboembolism</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of solid cancer and lymphoma</measure>
    <time_frame>Up to one year following venous thromboembolism</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">462</enrollment>
  <condition>Neoplasms</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Unprovoked VTE</arm_group_label>
    <description>Patients aged 40 years or older with a first episode of objectively confirmed, symptomatic, unprovoked deep vein thrombosis of the leg (distal or proximal) or pulmonary embolism</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Platelet pellet, EDTA plasma, citrated plasma, and cell-free DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients of 40 years or older with a first episode of objectively confirmed,
        symptomatic unprovoked distal or proximal deep vein thrombosis or pulmonary embolism.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First episode of objectively confirmed, symptomatic, unprovoked symptomatic pulmonary
             embolism and/or distal or proximal deep vein thrombosis of the leg

          -  Age 40 years or older

          -  Written informed consent

        Exclusion Criteria:

          -  known malignant disease prior to VTE defined as a cancer diagnosis or cancer treatment
             within the past 5 years (of note: suspected but unconfirmed cancer at diagnosis of VTE
             is allowed);

          -  trauma or fracture of the leg, surgical procedures, general anesthesia, or
             immobilization greater than 3 days within previous 3 months;

          -  previous unprovoked venous thromboembolism;

          -  known hereditary or acquired thrombophilia;

          -  current pregnancy or puerperium (up to 3 months postpartum);

          -  current estrogen therapy.

          -  Greater than 10 days after VTE diagnosis;

          -  Inability for blood withdrawal at baseline;

          -  Inability or refusal to provide written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry Büller, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Noémie Kraaijpoel, MD</last_name>
    <phone>0031205667050</phone>
    <email>n.kraaijpoel@amc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nick van Es, MD</last_name>
    <email>n.vanes@amc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Centre</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gary Raskob</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>KU Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Verhamme</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Carrier</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dresden University Clinic</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Beyer-Westendorf, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bologna University Hospital</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benilde Cosmi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gabriele D'Annunzio University</name>
      <address>
        <city>Chieti</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcello Di Nisio</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Padua</name>
      <address>
        <city>Padua</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Piccioli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Insubria</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Ageno</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noémie Kraaijpoel, MSc</last_name>
      <email>n.kraaijpoel@amc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Nick van Es, MD</last_name>
      <email>n.vanes@amc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Slotervaartziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Martin Otten</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VU medical center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Kramer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tergooiziekenhuizen</name>
      <address>
        <city>Hilversum</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pieter W Kamphuisen, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Klok</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Jara-Palomares, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Best MG, Sol N, Kooi I, Tannous J, Westerman BA, Rustenburg F, Schellen P, Verschueren H, Post E, Koster J, Ylstra B, Ameziane N, Dorsman J, Smit EF, Verheul HM, Noske DP, Reijneveld JC, Nilsson RJA, Tannous BA, Wesseling P, Wurdinger T. RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell. 2015 Nov 9;28(5):666-676. doi: 10.1016/j.ccell.2015.09.018. Epub 2015 Oct 29.</citation>
    <PMID>26525104</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Harry R. Buller</investigator_full_name>
    <investigator_title>Professor of Vascular Medicine</investigator_title>
  </responsible_party>
  <keyword>occult cancer</keyword>
  <keyword>venous thromboembolism</keyword>
  <keyword>tumor-educated platelets</keyword>
  <keyword>platelet RNA profiling</keyword>
  <keyword>early diagnosis</keyword>
  <keyword>screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

